GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • One trader’s very contrarian pharma trade Wednesday, 27 May 2015 | 10:22 AM ET

    Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.

  • CHICAGO/ NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps- importing eggs from overseas or looking to egg alternatives. A spokeswoman for Archer Daniels Midland Co said that as egg supplies tighten and prices rise, the food processing...

  • May 22- EU Medicines Agency:. *EU Medicines Agency recommendations for May 2015. *Recommends approval of cholesterol drug Repatha from Amgen Inc.

  • CHICAGO and NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps: importing eggs from overseas or looking to egg alternatives. "Canada is short on eggs and has been buying heavily from the U.S. for the last several years," said Rick Brown, a...

  • Europe ends sharply higher on ECB QE pledge Tuesday, 19 May 2015 | 11:30 AM ET

    European equities finished sharply higher, with investors reacting to corporate earnings and focusing on comments by a member of the ECB.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • Disruptor 50: No.1 Moderna Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.

  • Disruptor 50: No. 29 Intarcia Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Kurt Graves, CEO of Intarcia Therapeutics

    Investors believe Intarcia's drug-delivery system could very well upend the $55 billion worldwide market for treating Type-2 diabetes.

  • A hot biotech that may be the next Genentech Tuesday, 12 May 2015 | 7:00 AM ET
    Biotech

    This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • Spending on this type of meds hit a new milestone Tuesday, 5 May 2015 | 12:01 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher, following positive momentum from Europe, as investors looked to Fed speeches and data for signals on rate hike timing.

  • Top 5 stocks of the week and how to trade them Friday, 1 May 2015 | 2:21 PM ET
    Traders work on the floor of the New York Stock Exchange.

    CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.

  • DAX closes down 3%; Europe sells off as euro gains Wednesday, 29 Apr 2015 | 11:30 AM ET
    Federal Reserve building in Washington, D.C., U.S.

    European equities tumbled on Wednesday to close sharply lower as investors reacted to sharp gains in the euro against the dollar.

  • April 29- Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs. "This is going to be a much slower and much bigger effort over time than what you saw for hepatitis," Steve Miller, chief...